HLB Pharmaceutical Co., Ltd. (047920)

Overview

HLB Pharmaceutical Co., Ltd, originally known as Mediforum Pharmaceutical Incorporation until its renaming in October 2020, is a forefront pharmaceutical entity based in Namyangju, South Korea, that specializes in the development of peptide drugs. Founded in 1998, the company has carved a niche in the pharmaceutical industry by offering a wide range of medicinal products across various therapeutic categories. HLB Pharmaceutical is committed to innovation in healthcare, focusing on the development of advanced therapeutics including the promising CTT-004 for spinocerebellar degeneration-induced ataxia. Alongside its robust product portfolio, HLB Pharmaceutical extends its expertise through comprehensive Contract Manufacturing Organization (CMO) services, accommodating the complex needs of the pharmaceutical sector with high-quality standards.

Products and Services

• Skeletal Muscle Relaxants: Medications designed to alleviate muscle spasms or spasticity.
• Antihistamines: Drugs used to treat allergic reactions by blocking histamine action in the body.
• Antihypertensive Agents: Medicines aimed at managing high blood pressure to prevent cardiovascular diseases.
• Pain Relief and Anti-inflammatories: Products focused on reducing pain, inflammation, and discomfort in various conditions.
• Alimentary System and Metabolic Drugs: Treatments targeting digestive system disorders and metabolic issues.
• Ophthalmic Agents and Local Anesthetics: Medications for eye conditions and local anesthesia for minor surgical procedures.
• Cardiovascular and Central Nervous System Drugs: Treatments aimed at heart diseases and neurological conditions.
• Antibiotics and Chemotherapeutics: Agents to combat infectious diseases and cancer treatments.
• Dermatologicals and Skin Care Products: Treatments for skin conditions and products designed to maintain healthy skin.
• Agents for Liver Disease and Vitamins: Medicines for liver health support and a range of vitamin supplements for overall well-being.
• CMO Services: Comprehensive manufacturing services to third parties, ensuring high-quality production standards for a wide range of pharmaceutical products.
• CTT-004 Development: Ongoing research and development on CTT-004, a novel treatment aimed at addressing ataxia induced by spinocerebellar degeneration, showcasing the company’s commitment to advancing therapeutic solutions for complex medical conditions.